Advertisement
Canada markets open in 9 hours 22 minutes

  • S&P/TSX

    22,116.69
    -152.41 (-0.68%)
     

  • S&P 500

    5,283.40
    +5.89 (+0.11%)
     

  • DOW

    38,571.03
    -115.27 (-0.30%)
     

  • CAD/USD

    0.7333
    -0.0006 (-0.09%)
     

  • CRUDE OIL

    73.60
    -0.62 (-0.84%)
     

  • Bitcoin CAD

    94,256.70
    +1,089.93 (+1.17%)
     

  • CMC Crypto 200

    1,448.56
    -19.38 (-1.32%)
     

  • GOLD FUTURES

    2,366.30
    -3.00 (-0.13%)
     

  • RUSSELL 2000

    2,059.68
    -10.45 (-0.50%)
     

  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     

  • NASDAQ futures

    18,653.75
    +7.50 (+0.04%)
     

  • VOLATILITY

    13.11
    +0.19 (+1.47%)
     

  • FTSE

    8,262.75
    -12.63 (-0.15%)
     

  • NIKKEI 225

    38,803.41
    -119.59 (-0.31%)
     

  • CAD/EUR

    0.6719
    -0.0008 (-0.12%)
     

Theravance Biopharma to Participate in an Upcoming Investor Conference

PR Newswire
·2 min read

DUBLIN, May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT (8:30 AM PDT / 4:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.

Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)
Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

ADVERTISEMENT

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302140839.html

SOURCE Theravance Biopharma, Inc.